Author Archives: wpadmin

FDA Approves Inrebic (fedratinib) for the Treatment of Patients With Myelofibrosis

FDA Approves Inrebic (fedratinib) for the Treatment of Patients With Myelofibrosis Print this page SUMMIT, N.J.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved Inrebic (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.1 “The approval… Read More »

FDA Approves Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis

FDA Approves Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis Print this page NORTH CHICAGO, Ill., Aug. 16, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), a 15 mg, once-daily oral… Read More »

Tufts-Harvard Pilgrim combo portends increased use of IT

Harvard Pilgrim Health Care and Tufts Health Plan have announced intentions to combine, aiming to improve care quality through initiatives that will increase use of their information technology capabilities. The combination, announced on Wednesday, will join Harvard Pilgrim’s and Tufts’ not-for-profit organizations into a yet-to-be-named entity. Its board of directors will comprise equal representation from… Read More »